Pharmaceutical and Medical Device Manufacturing: Industry Report

Summary

Pharmaceutical and medical device manufacturing is a large industrial sector with continued growth expected. The latest available market research puts the global pharmaceutical manufacturing market at USD 627.8 billion, with North America holding 38% of revenue ². Forecasts differ by source: one projects revenue of about USD 1.3 trillion over the next five years ¹, while another projects USD 1,058.74 billion within its forecast period ². Digital adoption is uneven. In one vendor-linked benchmark, only 27% of surveyed contract manufacturers had integrated electronic batch records ³. Regulation is changing in both major markets. The U.S. quality system rule now incorporates ISO 13485 ⁵, and the EU is consulting on targeted changes to device rules ⁹. Principal risks include compliance cost, uncertain regulatory timing and gaps in workforce, pricing and quality data. The outlook is for continued growth, with more emphasis on quality systems and digital manufacturing, although the pace of regulatory change remains uncertain.

Key findings

1. 1

   The global pharmaceutical manufacturing market is forecast to keep expanding.

   Market research values the market at USD 627.8 billion in the latest available data and projects a 5.98% CAGR, reaching USD 1,058.74 billion in the forecast period. The forecast is an estimate, not a realized result.

   Confidence: Medium
2. 2

   Market size estimates are not consistent across sources.

   One market research firm reports 9,439 businesses and a forecast of USD 1.3 trillion, while another reports a different base value and forecast. The definitions differ, so the figures should be read as indicators, not a single market size.

   Confidence: Medium
3. 3

   Digital manufacturing adoption among contract manufacturers is limited.

   A vendor-linked benchmark of more than 50 global CDMOs found 27% had integrated electronic batch records and 25% used Manufacturing Execution Systems. The survey is not independently verified.

   Confidence: Qualitative
4. 4

   U.S. device quality rules now align with ISO 13485.

   The Quality Management System Regulation is in effect and incorporates ISO 13485 by reference. Under the QMSR, FDA inspections will not follow the MDSAP audit plan.

   Confidence: High
5. 5

   EU device rules are in a transition and possible revision phase.

   The MDR and IVDR apply, with some legacy transitional provisions postponed. The Commission published proposals to amend both regulations, but they have not yet been adopted, so existing transition periods still apply.

   Confidence: High

11. Industry definition and scope

This report covers the manufacture of pharmaceutical products and medical devices, with contract development and manufacturing organizations (CDMOs) treated as a provider type within the pharmaceutical segment ³. Geographic scope is global, with specific detail for the United States, where FDA regulates devices, and the European Union, where the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) apply ⁸¹⁰. The reporting period is the latest available data.

Terminology differs by source. Market research firms use terms such as pharmaceutical manufacturing, pharmaceutical and medicine manufacturing, and digital manufacturing in pharma ¹²³. Few of these sources cover medical device manufacturing as a separate market, so device figures are largely absent from the market-size evidence.

Segment detail is limited. The available data separates oral pharmaceutical products, which account for approximately 67% of the global market ². No verified segmentation for injectables, biologics or devices by revenue was retrieved.

Regulatory definitions also matter. In the United States, the device quality system rule now sits within FDA's current good manufacturing practice framework ⁶. In the EU, the MDR and IVDR set obligations for device makers and diagnostics makers ⁸¹⁰. Market figures do not map cleanly onto these regulatory categories.

Scope follows the source pack. Definitions are inferred from source titles and facts where the pack does not state a formal definition.

22. Market size, structure and value chain

Market research reports the global pharmaceutical manufacturing market at USD 627.8 billion in the latest available data, with North America holding a 38% revenue share ². That market is forecast to reach USD 1,058.74 billion, a 5.98% CAGR over the forecast period ². These are observed and forecast values from a single market research source.

A second market research source reports 9,439 businesses in the industry and a historical CAGR of 0.8%. It projects revenue growth of 1.9% a year to about USD 1.3 trillion over the next five years ¹. The two sources use different definitions and base values, so their figures cannot be reconciled from the pack. Readers should treat the forecasts as directional rather than precise.

Rising spending in emerging economies is cited as a factor in global expansion of pharmaceutical production ¹. This is a qualitative observation and the pack contains no regional production volumes to quantify it.

Value chain data are limited. The pack does not provide verified shares for active ingredient supply, formulation, fill and finish, packaging, or device component supply. Contract manufacturing appears as a distinct provider group ³, but its revenue share is not reported. Our interpretation is that the sector divides between companies that own products and manufacturers that serve them under contract, but this structure is not quantified in the sources.

• Global pharmaceutical manufacturing market value 627.8USD billion Observed Global, Latest available data [2]
• Share of market from oral pharmaceutical products 67percent Observed Global, Latest available data [2]
• Businesses in the global pharmaceutical and medicine manufacturing industry 9,439businesses Observed Global, Latest available data [1]

Values are reported as published. No independent reconciliation was possible with the source pack.

33. Customers, demand and adoption

Direct customers of manufacturers include pharmaceutical developers that outsource production and companies that sell finished products. Downstream end users are patients and health systems. The pack contains no verified data on prevalence, treatment volumes, or patient demand for manufactured products, so demand cannot be quantified beyond market forecasts ¹².

Purchasing criteria in the sources center on quality and regulatory compliance. In the United States, the device quality system rule requires manufacturers to meet ISO 13485 requirements ⁵⁶. Customers of contract manufacturers therefore expect documented quality systems that match these standards. Our interpretation is that compliance capability is a central selection factor, although the pack does not measure buyer preferences.

Digital adoption is a visible barrier. Only 27% of surveyed CDMOs had integrated electronic batch records, and 25% used Manufacturing Execution Systems ³. These are vendor-linked figures and the survey is not independently verified.

Investment commitments show where manufacturers are expanding. Gilead Sciences announced USD 32 billion toward U.S. manufacturing and research expansion, and Novartis pledged USD 23 billion over five years ⁴. These are company announcements, not verified capacity data.

Affordability, pricing and equity are not covered by the pack. No verified pricing, reimbursement or access data for manufactured products were retrieved, so this report cannot assess cost pressure on patients or health systems.

Customer analysis relies on regulatory and vendor-derived evidence. No buyer survey data were available.

44. Competitive landscape and key players

The pack does not provide verified market shares or concentration ratios for individual companies. The only regional share is North America's 38% of revenue in the pharmaceutical manufacturing market ². Competitive structure therefore has to be described by provider type rather than ranked by share.

Large innovator pharmaceutical companies are one provider type. Gilead Sciences committed USD 32 billion to U.S. manufacturing and R&D expansion, and Novartis pledged USD 23 billion over five years to expand U.S. operations ⁴. The two commitments differ in scope and timing, and the pack gives no completion data, so their effect on capacity is unverified.

Contract manufacturers form a second provider type. The benchmark covered more than 50 global CDMOs ³. The pack does not give their revenue, capacity or customer mix, so comparison with innovator companies is limited to digital capability and reported adoption.

Medical device manufacturers are not covered by named company examples in the pack. Comparable device company data were limited, and no public, private or community manufacturing comparison was retrieved.

Our interpretation is that competitive pressure is shifting toward regulatory readiness and digital process capability. This is an assessment from the regulatory and benchmark sources, not a measured finding.

Examples are drawn only from the source pack and are described as announcements.

55. Technology, operations and workforce

Batch manufacturing remains the established operating model in the pack's sources. Electronic batch records and Manufacturing Execution Systems are common tools for managing production records, but the survey shows that most CDMOs have not integrated them: 27% had integrated electronic batch records and 25% used Manufacturing Execution Systems ³. These figures come from a vendor-linked benchmark that is not independently verified.

Continuous manufacturing is presented as an emerging approach. Research cited in the vendor report estimates that continuous manufacturing can cut equipment footprint by up to 70% ³. This is an estimate and the pack does not show how widely it is adopted or what it costs to implement.

Workforce data are not available. The pack contains no verified data on staffing, shortages, wages or training for pharmaceutical or device manufacturing. Our interpretation is that quality systems and digital manufacturing require staff with compliance and data skills, but the pack does not measure this demand.

Business model change is linked to these technologies. Shifting toward integrated digital records and smaller footprints may change how contract manufacturers compete, but the sources do not quantify productivity gains outside the footprint estimate.

• CDMOs with integrated electronic batch records 27percent of surveyed CDMOs Observed Global, Latest available data [3]
• Potential equipment footprint reduction from continuous manufacturing 70percent, up to Estimate Global, Latest available data [3]

Digital adoption figures are from a single vendor-linked survey.

66. Regulation, standards, risk and sustainability

United States (binding): FDA's Quality Management System Regulation is in effect and incorporates ISO 13485 by reference ⁵. A final rule amended device current good manufacturing practice requirements to align with ISO 13485 ⁶. FDA has stated that QMSR inspections will not follow the MDSAP audit plan or procedures ⁶. Legacy inspection documents were withdrawn once the rule took effect ⁵.

United States (proposed or guidance): FDA issued draft guidance on quality system information for certain premarket submission reviews under the QMSR ⁷. Draft guidance is not binding and its final content may change.

European Union (binding): The MDR came into force and became applicable, with certain provisions postponed until later for devices approved under former directives or covered by earlier declarations of conformity ⁸. The IVDR has also applied ¹⁰.

European Union (proposed): The Commission published proposals in December to amend the MDR and IVDR ⁹. As of the latest available commentary, the regulations had not been amended, so existing transition periods still apply ⁹. The proposal initiates a targeted revision ¹⁰. Industry commentary reports that EUDAMED core module timing is an expectation, not a confirmed date, so it is treated here as unverified.

Ethics, privacy, environmental and social factors are not covered by the pack. Sustainability and safety outcomes, including recall rates and inspection results, were not retrieved ¹². This report does not provide legal or regulatory advice.

Binding rules are separated from proposals and guidance. Jurisdiction is stated for each item.

77. Challenges, opportunities and case examples

Regulatory timing is the most visible constraint. The U.S. rule is in effect ⁵⁶, but the EU revision is still a proposal, so device makers face parallel obligations ⁹¹⁰. Manufacturers that sell in both markets must plan for transitional periods that may change.

Capital intensity is a second constraint. The Gilead and Novartis commitments show the scale of investment in U.S. operations ⁴. The pack gives no outcome data for these programs, so the return on such investment cannot be assessed.

Digital adoption offers room for improvement. The benchmark found that most surveyed CDMOs had not integrated electronic batch records or Manufacturing Execution Systems ³. Our interpretation is that tighter integration could support compliance, although the survey does not measure outcomes.

Case examples: Gilead Sciences (U.S. manufacturing and R&D commitment of USD 32 billion) and Novartis (USD 23 billion pledged over five years for U.S. operations) show large pharmaceutical companies investing in domestic capacity ⁴. Comparable device manufacturer examples were limited in the pack.

Case examples are limited to sourced announcements and a single benchmark.

88. Outlook and strategic implications

Base case: market research forecasts continued growth in pharmaceutical manufacturing, with a 5.98% CAGR projected ² and revenue expansion forecast by another source ¹. These forecasts depend on assumptions the pack does not disclose, so growth should be treated as likely but uncertain.

Regulatory scenario: the U.S. quality system framework is set, while EU device rules may change once the Commission proposals progress ⁹¹⁰. Manufacturers should plan for both the current rules and possible amendments. Transition timing for legacy EU devices remains a near-term issue ⁸⁹.

Digital scenario: adoption among CDMOs is low in the benchmark ³, so there is room for growth in integrated records and production systems. Continuous manufacturing is a possible efficiency path, but its adoption and cost are not verified in the pack.

Implications for stakeholders: manufacturers should align quality systems with ISO 13485 and track EU transition deadlines. Contract manufacturers should evaluate digital record and production systems against the reported adoption gap. Investors and policymakers should request verified data on workforce, pricing and quality performance, which the pack does not provide.

Outlook combines forecasts with regulatory status. It is not investment or regulatory advice.

99. Conclusion

The sector is large and forecast to grow, but market estimates vary by source and definition. The most defensible takeaways are that U.S. device quality rules now align with ISO 13485 ⁶, EU device rules are in transition ⁹, and digital manufacturing adoption among surveyed CDMOs is limited ³.

How this was built

Sources

1. 1

   Global Pharmaceutical & Medicine Manufacturing Industry Analysis

   IBISWorld Market research

   ibisworld.com
2. 2

   Pharmaceutical Manufacturing Market Size & Industry Outlook

   Fortune Business Insights Market research

   fortunebusinessinsights.com
3. 3

   Digital Manufacturing in Pharma: Market Trends and Forecast

   PharmaSource, with MasterControl benchmarking data Vendor report

   pharmasource.global
4. 4

   Pharmaceutical Manufacturing Market Size, Share

   M2Square Consultancy Market research

   m2squareconsultancy.com
5. 5

   Quality and Compliance (Medical Devices)

   U.S. Food and Drug Administration Regulator

   fda.gov
6. 6

   Quality Management System Regulation, Frequently Asked Questions

   U.S. Food and Drug Administration Regulator

   fda.gov
7. 7

   Quality Management System Information for Certain Premarket Submission Reviews (draft guidance)

   U.S. Food and Drug Administration Regulator

   fda.gov
8. 8

   Medical Device Regulation (MDR)

   TÜV SÜD Vendor report

   tuvsud.com
9. 9

   The EU Medical Device Shake-Up: What International Companies Should Prepare

   Arnold & Porter News report

   arnoldporter.com
10. 10

    The EU Medical Device Regulation (MDR): What changes?

    VDE Industry association

    vde.com